Sign Up
Stories
GLP-1 Agonists and Weight-Loss Drugs Dominate Q3 Earnings Calls
Share
Diabetes Drug Markets' Growth and Domina...
Eli Lilly Acquires Versanis Bio
Eli Lilly to Build $2.5B Plant for Weigh...
Amgen's Weight-Loss Drugs Market Entranc...
Analyst Recommendations Impact Diverse C...
Anti-Obesity Meds' Impact on Allurion Pr...
Overview
API
GLP-1 agonists, such as Wegovy, Ozempic, and Mounjaro, were a hot topic during Q3 earnings calls. Novo Nordisk unseated LVMH as Europe's most valuable listed company. Retail investors have been flocking to Eli Lilly after its weight-loss drug Zepbound received approval.
Ask a question
How might the popularity of GLP-1 agonists impact the sales of other drugs?
What are the potential implications of retail investors' interest in weight-loss drugs?
What factors contributed to Novo Nordisk's surpassing of LVMH?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Aug 2023
Sep 2023
Oct 2023
Nov 2023
Coverage